Management of Management of Locally Advanced Locally Advanced

NSCLCNSCLC

Management of Management of Locally Advanced Locally Advanced

NSCLCNSCLCShilpen Patel MD FACRO

Department of Radiation Oncology, University of Washington, Seattle, WA

Roadmap• Background

•Evolution of therapy

•Radiation alone

•Sequential chemotherapy and radiation

•Concurrent chemotherapy and radiation

•Trimodality versus bimodality

•Superior Sulcus Tumors

•Imaging

Survival Improvement in Stage III NSCLC since 1980’s

5

7

9

11

13

15

17

19

1980's 1990's 2000's

me

dia

n s

urv

iva

l

CALBG

Finish

IGR

NCCTG

WJLCG

GLOT

CZECH

LAMP

RTOG 9410

MUNICH

ECOG 2597

9.89.8

13.813.8

17.717.7

Evolution: Radiation Alone

• In the 1970’s stage III NSCLC was an unresectable disease

• Standard of care was radiation alone

RTOG 73RTOG 73--0101----Perez, et alPerez, et alCancer 45: 2744, 1980. Update Cancer 59: 1874, 1987.Cancer 45: 2744, 1980. Update Cancer 59: 1874, 1987.

Dose escalation trial of 365 pts w/ T3 Dose escalation trial of 365 pts w/ T3 or N2 NSCLC randomized to 4 arms, or N2 NSCLC randomized to 4 arms, each utilizing radiotherapy alone:each utilizing radiotherapy alone:Dose In-field

recurrenceMediansurvival

3 yearsurvival

40Gy split course 53% 37wks 6%40Gy conventional 58% 45wks 6%50Gy 49% 41wks 10%60Gy 35% 47wks 15%

Evolution: Sequential chemotherapy and radiation

Dillman et al. Improved Survival in Stage III NSCLC: 7yr f/u of CALGB #8433. JNCI Vol 88,

No 17: 1210-14, 1990 & 1996

• 165 Pts w/ stage III NSCLC randomized to:

Cisplatin + vinorelbine

Radiation--60Gy

Radiation--60Gy

Dillman et al. Improved Survival in Stage III NSCLC: 7yr f/u of CALGB #8433. JNCI Vol 88,

No 17: 1210-14, 1990 & 1996

• Median survival improved with chemotherapy– 9.7 months with radiation alone– 13.8 months with chemotherapy and radiation

• OS improved at 7 years:– 6% with radiation alone– 13% with chemotherapy and radiation

Evolution: Concurrent Chemoradiation

RTOG 94-10: Curran, et al, J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60

RANDOMIZATION

cDDP 100 mg/m2 d1, 29Vlb 5 mg/m2 Q wk X 5 (d1, 8, 15, 22, 29)Standard fractionated RT (60 Gy) d 50

cDDP 100 mg/m2 d1, 29Vlb 5 mg/m2 Q wk X 5 (d1, 8, 15, 22, 29)Standard fractionated RT(60 Gy) d1

cDDP 50 mg/m2 d1, 8, 29, 36VP-16 50 mg/m2 d1-5, 8-12, 29-33, 36-40Hyperfractionated RT (69.6 Gy) d1

CON- QD

CON- BID

SEQ

RTOG 94-10: Curran, et al, J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60

Courtesy of Walter Curran, MD

RTOG 94-10: Curran, et al, J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60

Courtesy of Walter Curran, MD

RTOG 94-10: Curran, et al, J Natl Cancer Inst. 2011 Oct 5;103(19):1452-60

In Field failure rates

– Sequential: 38%

– Concurrent: 33%

– Hyperfractionated: 25%

0

10

20

30

40

50

60

70

80

90

100

1980's 1990's 2000's

Lo

ca

l C

on

tro

lLocal ControlLocal Control

65% 65% 65%

Evolution: Trimodality

Intergroup 0139- Albain, et al., 2009

Stage IIIA (T1-3, pN2,

M0)NSCLCN = 429

(396 eligible)

Considered Resectable

RANDOMIZE

Cis/VP16 x 2 cycles

w/concurrent XRT 45Gy

Cis/VP16 x 2 cycles

w/concurrent XRT 45Gy

Surgery

Cis/VP16 x 2 cycles

Cis/VP16 x 2 cycles

Re-evaluate 2 to 4 weeks post RT; if no PD

Re-evaluate 7 days prior to RT completion; if no PD

Continue RT to 61GY

Median F/U 81 months

Results: Intergroup 0139

Courtesy of Kathy Albain, MD

Intergroup 0139/RTOG 9309 Progression-Free Survival by Treatment Arms

Per

cen

t A

live

Months

Trimodality ( n=201)Median 12.8 months5-year 22.4%

Chemoradiation (n=191)Median 10.5 months5-year 11.1%

0

20

40

60

80

100

0 6 12 18 24 30 36 42 48

/

// //

/

// // / / / /// / / / / //

//

// /////

// / // / / ////// // // / // // //////

Log rank p = 0.017

Intergroup 0139/RTOG 9309 Lancet 8/1/09

Independent Favorable Survival Predictors •Female

•No weight loss

•Trimodality Arm–pN0 OS=41%–pN1-3 OS=24%–No SurgeryOS=8%

Joshua Sonett, MD, et al Pulmonary Resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in NSCLC. Ann Thor Surg 2004;78(4)•40 consecutive patients who received high dose radiotherapy and concurrent platinum based chemotherapy between January 1994-May 2000 who then went on to undergo a lung resection.

•Patients–Stage IIB – 7 patients

–Stage IIIA – 21 patients

–Stage IIIB – 10 patients

–Stage IV – 2 patients

Surgery •Median time to surgical resection 52.5 days (20-258 days)

•Surgeries

–29 lobectomies

–11 pneumonectomies

•No post-operative deaths

•Median ICU time = 2 days

•Overall length of stay = 6 days

•One patient developed post pneumonectomy pulmonary edema

•One patient developed a BP fistula

Results

•34/40 patients (85%) were downstaged pathologically

•33/40 patients (82.5%) had no residual lymphadenopathy

•18/40 patients (45%) exhibited a complete pathologic response

•22/26 patients (85%) with N2 disease exhibited pathologic confirmed sterilization of their mediastinal disease

Results

•Median follow-up was 2.8 years

•Overall survival at 1,2, and 5 years is 92%, 67%, 46% respectively. Median overall survival 53 months.

•Disease free survival at 1, 2, and 5 years is 73%, 67%, 56%. Median disease free survival not reached

•Failure Pattern–14% Local and distant

–29% Brain only

–29% Distant only

–29% Local only

RTOG 0229, Suntharalingam IJROBP 2012

Stage III (pathologically proven N2 or N3)NSCLC

N = 60 (57 eligible)

CBDCA AUC =2.0,

paclitaxel 50 mg/m2 q week x 6, 50.4 Gy to

the mediastinum and primary tumor and

boost of 10.8 Gy to gross

dz

Surgery

CBDCA AUC =6,

paclitaxel 200 mg/m2 q 21d x 2.

Re-evaluate 2 to 4 weeks post RT; if no PD

Median follow-up is 20 months.

RTOG 0229, Suntharalingam IJROBP 2012

• Grade 3/4 toxicities: heme 35%, GI 14%, pulmonary 23%.

• 43 pts (75%) were evaluable for the primary endpoint; 36 pts underwent resection. 7 pts had residual mediastinal dz. 27/43 (63%) achieved mediastinal clearance.

• There was a 14% (5/37) incidence of grade 3 postoperative pulmonary complications. There was only one postop grade 5 toxicity (3%).

RTOG 0229, Suntharalingam IJROBP 2012

• With a median follow-up of 24 months for all patients, the 2-year overall survival rate was 54%, and the 2-year progression-free survival rate was 33%. The 2 year survival rate was 75% for those who achieved nodal clearance.

• Next steps? RTOG 0839

Thomas M, Macha HN, Ukena D, et al. Cisplatin/etoposide followed by twice daily chemoradiation versus cisplatin/etoposide alone before surgery in Stage III

NSCLC: A randomized Phase III trial of the GermanLung Cancer Cooperative Group. Lancet Oncology 2008

Thomas M, Macha Et al. Lancet Oncology 2008.• Only 54-57% of Stage IIIA patients in either arm

underwent a complete resection (R0)• MST was not different between the arms (15.5 mo.

in chemoradiotherapy and 16.8 mo. in chemotherapy only arm, p=0.97)

• Radiation was delivered in a non standard form (and we know from RTOG 9410 that BID is inferior!)

• Pneumonectomy contributed to mortality (14% versus 6%)

Van Meerbeeck et al JNCI 99(6) p 442-450 EORTC 08941

• 579 pts stage IIIA N2 NSCLC randomized:Platinum based

chemo

Radiation--60Gy

Surgical Resection

Radiation

Van Meerbeeck et al JNCI 99(6) p 442-450 EORTC 08941

• In the XRT arm, g 3/4 acute and late esophageal and pulmonary toxicity was 4% and 7%

• Median and 5 y Overall survival (resection versus XRT) was 16.4 versus 17.5 mo and 15.7% versus 14%

Is long term survival predicted by pathologic response?/Does mediastinal clearance matter?

•Rusch VW, Albain KS, Crowley JJ, et al Surgical Resection of Stage IIIA/IIIB NSCLC after induction chemoradiotherapy. J. Thorac Cardiovasc Surgery 1993;105:96-106

•Sugarbaker DJ, Herdon J, Kohman LJ, Krasna MJ, Green MR, CALGB Thoracic Surgery Group. Results of CALGB 8935. A multiinstitutional phase II trimodality trial for Stage IIIA NSCLC. J Thorac Cardiovasc Surg 1995; 109; 473-83

•Voltoni L, Luca L, Ghiribelli C, Paladini P, Di Bisceglie M, Gotti G. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA NSCLC; the importance of nodal down staging after chemotherapy. Eur J Cardiothoracic Surg 2001;20:1106-12.

•Betticher DC, Schmitts S, Totsch M, et al Mediastinal lymph node clearance after docetaxol-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 NSCLC:a multicenter phase II trial JCO 21:1752-9.

What about superior sulcus tumors?

SWOG 9416

Pancoast tumors (n=83)

Cis/Etoposide + XRT 45 Gy

Surgery 2 cycles

of chemo

Re-evaluate 2 to 4 weeks post RT; if no PD

Kwong KF, et al High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. J Thorac Cardiovasc Surg. 2005

Jun;129(6):1250-7

• 36 patients with Pancoast tumor• Stage IIB-IV • R0 resection was achieved in 36 (97.3%) patients• High-dose radiotherapy (mean 56.9Gy; range, 30-

70.2 Gy) was successfully tolerated in all but 1 patient

• Pathologic complete response was found in 40.5% (n = 15) of patients

Kwong KF, et al . J Thorac Cardiovasc Surg. 2005 Jun;129(6):1250-7

• Operative mortality rate was 2.7% (n=1/37).

• Significant morbidities occurred in 10 patients (n=10/37, 27% patients) but were variable and without a dominant pattern

• Recurrences occurred in 50% of patients

• Distant recurrence accounted for the majority of recurrences (13 patients / 36.1%)

• Local recurrences in the lung-mediastinum occurred in 5 patients (13.8%)

Kwong KF, et al . J Thorac Cardiovasc Surg. 2005 Jun;129(6):1250-7

Kwong KF, et al . J Thorac Cardiovasc Surg. 2005 Jun;129(6):1250-7

New technology requires careful planning

• Treatment planning cannot make up for drawing the wrong volumes

• The most radioresistant tumor cell is the one that’s not in the field!

What about PET?

Assessing Gross Tumor Volume

Imaging in Lung CancerAssessing Gross Tumor Volume

CT-then-PET Registration

PET-CT

Staging – PET/CT

What Respiratory 4D PET/CT Will Show

…

…

4D PET (tomorrow)3D PET (today)

}

Imaging Questions

Imaging Questions• When is the tumor within my fields?

– Tumor motion, mostly respiratory– 4D CT– Does motion change during Rx?

• Infection• Response to Rx• How often should we re-measure motion?

– Who would most benefit?

• How does the tumor change shape during Rx?– Second-to-second– Day-to-day

Benefits of Cone Beam CT

Imaging Questions for Radiation Oncology

– Normal tissue function/risk?• Interpatient differences

– Radiosensitivity– Underlying disease– Pretreatment vs. post treatment imaging

• Can Dose/function histograms be developed?

Should we incorporate SPECT?

Voxel-by-voxel ventilation

Ventilation

Ventilation

Imaging Questions for Radiation Oncology

– How do you account for these changes with IMRT or protons?

– How do doses add together? – How do we image biology?

• Tumor?

– SUV?– MR Spectroscopy?– Hypoxia, other markers?

Take Home Points• Current standard of care for stage

IIIA/IIIB NSCLC continues to be defined• Trimodality is reasonable option on

study and/or with well informed patients– Role of surgery should be based

• Nodal Status

• Performance Status

• Surgeon experience

Take Home Points

• Success of trimodality depends on:– Good radiotherapy techniques– Good surgical techniques

• Higher doses of radiation pre-operatively may improve outcomes

• Imaging will grow in importance in oncology